Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPONSE phase 3 trial of seladelpar in primary biliary cholangitis
NL-OMON52199Phase 3Completed
- Sponsor
- CymaBay Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Seladelpar with Placebo (2 arms). Primary endpoints: Composite biochemical response at 12 months and Safety over 12 months. Started May 2022; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON52199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52199.